Thymic peptides in Furgal’s military immunization research
S. M. Furgal · 1996 · Kirov Military Medical Academy doctoral dissertation author abstract, 52 pp.
Related evidence maps: Military & occupational ↗
Reported findings and study design
The donor immunization program reported 83.7% or more immune responders with thymic peptide adjuncts versus 60.5% with standard toxoid vaccination. The source does not isolate a reliable effect for either peptide.
7,630 across thirteen military units in the immunocorrection series. The 240-person donor series included multiple approaches.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Staphylococcal toxoid donor program · immune responders | ≥83.7% with the peptide-inclusive approach versus 60.5% with standard vaccination | Thymalin and Thymogen were discussed within the 240-person donor series. Individual treatment-arm sizes are unresolved. |
| Reported antibody titres | ≥9.6±0.2 versus 8.6±0.7 IU/mL | Donor comparison; uncertainty term and exact n not verified. |
| Reported duration of humoral response | At least 20 weeks versus 6–8 weeks | Author’s interpretation of donor antibody response. Clinical infection protection requires separate evidence. |
| Reported immunocorrection series | 7,630 across thirteen military units | Eleven reported series with observation periods of 4–24 months. Includes peptide and nonpeptide approaches. |
This source documents military immunology and infection-prevention research. The program total spans multiple interventions and controls.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Do not treat the donor antibody results as prevention of infection or proof of improved work performance.
- The summarized findings do not resolve whether Thymalin and Thymogen were used together or in distinct regimens.
- Original denominators and allocation are needed to estimate uncertainty.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Author abstract, eleven series and archival report citations checked. Original treatment-arm tables remain unavailable.
Review depth: Reported methods, results and evidence limitations
Source access and review scope
Author abstract, eleven series and archival report citations checked. Original treatment-arm tables remain unavailable.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Dissertation
Citation and original source
Original source: S. M. Furgal. Thymic peptides in Furgal’s military immunization research Kirov Military Medical Academy doctoral dissertation author abstract, 52 pp. 1996.
Molekul research summary: https://molekul.io/research/furgal-thymic-peptides-immunization-1996. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Thymalin
Thymus-derived peptide mixture with historical Russian studies in autoimmune cytopenias and thyroiditis, alongside other treatments. It is distinct from synthetic Thymogen and Thymodepressin.
Thymogen
EW is discussed in the thymus-derived research program. Thymalin extract outcomes cannot be assigned to this defined peptide.